Clinicopathological Analysis of Pure and Mixed Subtypes of Mucinous Breast Carcinoma: A Cross-sectional Study
Introduction: Mucinous Breast Carcinomas (MC) are rare, comprising approximately 2% of breast cancers. These tumours are classified into Pure Mucinous Carcinoma (PMC) and Mixed Mucinous Carcinoma (MMC), each with distinct clinical behaviours. Aim: To analyse and compare clinicopathological profiles...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2025-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/20783/77895_CE[Ra1]_F(SS)_QC(PS_IS)_PF1(JY_SS)_redo_PFA(IS)_PB(JY_IS)_PN(IS).pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Mucinous Breast Carcinomas (MC) are rare, comprising approximately 2% of breast cancers. These tumours are classified into Pure Mucinous Carcinoma (PMC) and Mixed Mucinous Carcinoma (MMC), each with distinct clinical behaviours.
Aim: To analyse and compare clinicopathological profiles, hormone receptor status, pathological staging and treatment modalities between PMC and MMC, while studying their prognostic differences by assessing their status of lymph node metastasis, tumour staging and tumour grades.
Materials and Methods: A retrospective cross-sectional study was conducted in the Department of Pathology, Christian Medical College, Vellore, Tamil Nadu, India, from January 2017 to December 2021. Data from 71 cases of MC were reviewed for clinicopathological parameters, treatment modalities and outcomes. Chi-square test and Fisher’s exact test were performed to compare various characteristic features between patients with PMC and MMC.
Results: Out of 71 participants, there were 2 (2.82%) males and 69 (97.18%) females. MC accounted for 3.4% (71 MC out of 2,043 breast carcinomas) of breast carcinomas. Of the 71 cases, 82% were PMC and 18% were MMC. MMCs showed higher tumour grades, lymphovascular invasion (61.5% vs. 10.9%, p-value <0.05), and lymph node metastasis (38% vs. 9%, p-value <0.05) compared to PMCs. Hormonal profiles predominantly exhibited the luminal A type (85.9%), with only 8.4% being Human Epidermal growth factor Receptor 2 positive (HER2-positive) tumours. The median follow-up was 28 months, with excellent survival outcomes for PMCs but a higher recurrence risk for MMCs.
Conclusion: The PMCs have favourable outcomes, while MMCs require more aggressive management due to a poorer prognosis. Differentiating between these subtypes is crucial for tailoring treatment strategies. |
|---|---|
| ISSN: | 2249-782X 0973-709X |